Ines Vasconcelos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ines Vasconcelos has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
Winfried Schoenegg
Praxis für Brusterkrankungen, Berlin, Germany
6 shared publicationsJalid Sehouli
Department of gynecology Campus Virchow, Charité Medical University of Berlin, Germany
3 shared publicationsFriederike Siedentopf
Praxis für Brusterkrankungen, Berlin, Germany
2 shared publicationsIoana Braicu
Department of gynecology Campus Virchow, Charité Medical University of Berlin, Germany
2 shared publicationsJessica Olschewski
Department of gynecology Campus Virchow, Charité Medical University of Berlin, Germany
2 shared publicationsJörg Linke
Gemeinschaftspraxis für Pathologie am Bundeswehrkrankenhaus, Scharnhorststrasse 13, 10115 Berlin, Germany
2 shared publications
Latest Publications
- 12 September 2019
- Published by Hindawi Limited in The Breast Journal
- Vol. 26 (3) , 553-555
Acellular dermal matrices safety in breast reconstruction—Is it truly associated with higher rates of complications? A large single‐surgeon cohort analysis
Click on the article title to read more.
- 12 September 2019
- Published by Hindawi Limited in The Breast Journal
- Vol. 26 (3) , 553-555
Acellular dermal matrices safety in breast reconstruction—Is it truly associated with higher rates of complications? A large single‐surgeon cohort analysis
Click on the article title to read more.
- 1 August 2018
- Published by Elsevier in The Breast
- Vol. 40, 1-3
Scalp cooling successfully prevents alopecia in breast cancer patients undergoing anthracycline/taxane-based chemotherapy
- 1 August 2018
- Published by Elsevier in The Breast
- Vol. 40, 1-3
Scalp cooling successfully prevents alopecia in breast cancer patients undergoing anthracycline/taxane-based chemotherapy
- Open Access
- 1 October 2016
- Published by Elsevier in The Breast
- Vol. 29, 181-185
The St. Gallen surrogate classification for breast cancer subtypes successfully predicts tumor presenting features, nodal involvement, recurrence patterns and disease free survival
- 1 October 2016
- Published by Elsevier in The Breast
- Vol. 29, 181-185
Open AccessThe St. Gallen surrogate classification for breast cancer subtypes successfully predicts tumor presenting features, nodal involvement, recurrence patterns and disease free survival
- 25 December 2015
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 123 (4) , 498-508
Serous and mucinous borderline ovarian tumours: differences in clinical presentation, high‐risk histopathological features, and lethal recurrence rates
Background: Mucinous and serous borderline ovarian tumours (mBOTs and sBOTs) are controversial diseases.Objectives: With this systematic review we aim to evaluate the different high‐risk histopathological features and recurrence rates.Search strategy: The PubMed database was searched using two terms: {serous AND [(borderline) OR (low malignant potential)] AND ovarian AND tumour} and {mucinous AND [(borderline) OR (low malignant potential)] AND ovarian AND tumour}.Selection criteria: Cohorts of either sBOT or mBOT, peer‐reviewed, retrospective, or prospective.Data collection and analysis: Lethal recurrence data for micropapillary patterns (MPs), microinvasion, non‐invasive and invasive implants, and intraepithelial carcinoma (IECA). The primary measure of effect was the odds ratio of lethal recurrence reduction.Results: Data from patients in 42 studies including 4414 sBOTs and 12 studies including 894 mBOTs were pooled. Of these, 53.3% presented early‐stage typical sBOTs, 24.4% presented with MPs, 22.3% presented with microinvasion, 34.4% presented with non‐invasive implants, and 7.3% presented with invasive implants. The pooled lethal recurrence rates were, respectively: 18.3, 16.8, 10.7, 16.2, and 33.8%. Patients with MPs were more likely to suffer lethal recurrence when compared with high‐stage sBOTs (odds ratio, OR 0.501; P = 0.003), whereas the trend in microinvasive sBOTs did not reach statistical significance. Regarding mBOTs, 61.6% presented with early‐stage typical mBOTs, 19.6% presented with microinvasion, 34.8% presented with IECA, and six patients presented with non‐invasive implants; none presented with invasive implants. The lethal recurrence rates were, respectively: 3.6, 0, 3.7, and 0%.Conclusion: Micropapillary patterns (MPs) showed a higher risk for lethal recurrence when compared with high‐stage sBOTs. Regarding mBOTs, IECA and microinvasion do not play a role in the lethal recurrence rate.Tweetable Micropapillary pattern confirmed as high‐risk in BOT. IECA and microinvasion don't play a role in mucinous BOT.
- 25 December 2015
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 123 (4) , 498-508
Serous and mucinous borderline ovarian tumours: differences in clinical presentation, high‐risk histopathological features, and lethal recurrence rates
Background: Mucinous and serous borderline ovarian tumours (mBOTs and sBOTs) are controversial diseases.Objectives: With this systematic review we aim to evaluate the different high‐risk histopathological features and recurrence rates.Search strategy: The PubMed database was searched using two terms: {serous AND [(borderline) OR (low malignant potential)] AND ovarian AND tumour} and {mucinous AND [(borderline) OR (low malignant potential)] AND ovarian AND tumour}.Selection criteria: Cohorts of either sBOT or mBOT, peer‐reviewed, retrospective, or prospective.Data collection and analysis: Lethal recurrence data for micropapillary patterns (MPs), microinvasion, non‐invasive and invasive implants, and intraepithelial carcinoma (IECA). The primary measure of effect was the odds ratio of lethal recurrence reduction.Results: Data from patients in 42 studies including 4414 sBOTs and 12 studies including 894 mBOTs were pooled. Of these, 53.3% presented early‐stage typical sBOTs, 24.4% presented with MPs, 22.3% presented with microinvasion, 34.4% presented with non‐invasive implants, and 7.3% presented with invasive implants. The pooled lethal recurrence rates were, respectively: 18.3, 16.8, 10.7, 16.2, and 33.8%. Patients with MPs were more likely to suffer lethal recurrence when compared with high‐stage sBOTs (odds ratio, OR 0.501; P = 0.003), whereas the trend in microinvasive sBOTs did not reach statistical significance. Regarding mBOTs, 61.6% presented with early‐stage typical mBOTs, 19.6% presented with microinvasion, 34.8% presented with IECA, and six patients presented with non‐invasive implants; none presented with invasive implants. The lethal recurrence rates were, respectively: 3.6, 0, 3.7, and 0%.Conclusion: Micropapillary patterns (MPs) showed a higher risk for lethal recurrence when compared with high‐stage sBOTs. Regarding mBOTs, IECA and microinvasion do not play a role in the lethal recurrence rate.Tweetable Micropapillary pattern confirmed as high‐risk in BOT. IECA and microinvasion don't play a role in mucinous BOT.
- 22 September 2015
- Published by Hindawi Limited in The Breast Journal
- Vol. 21 (6) , 681-682
Hidradenoma of the Breast: A Source of Diagnostic Confusion
- 22 September 2015
- Published by Hindawi Limited in The Breast Journal
- Vol. 21 (6) , 681-682
Hidradenoma of the Breast: A Source of Diagnostic Confusion
Sudden onset diffuse erythema and oedema of the breast
A 40 year old premenopausal white woman presented to a general gynaecologist with diffuse redness, swelling, and rapidly progressive pain in her left breast. She did not have a fever. Her medical history included one full term pregnancy with spontaneous delivery 19 years earlier. Her maternal grandmother had died of breast cancer at age 65 years. On physical examination, a warm and painful diffuse oedematous erythema was found in the inner quadrants of the breast (fig 1⇓), but she was otherwise in good general health. ### 1. On the basis of the history and examination findings, what are the differential diagnoses and the probable diagnosis? #### Short answer Non-lactational mastitis, cellulitis, abscess, and inflammatory breast cancer (IBC). Figure 1⇑ shows a classic presentation of IBC. #### Discussion Breast masses require triple test evaluation—physical examination, radiological examination, and needle biopsy—the results of which must all agree. IBC is diagnosed on clinical grounds, so the physical examination is key. The classic findings are diffuse erythema and oedema with bulging intradermal lymphatics enveloping more than a third of the breast, as well as the absence of systemic symptoms such as malaise and fever. The differential diagnosis in this setting, based on the physical examination, includes non-lactational mastitis, cellulitis, abscess, and inflammatory breast cancer. Non-lactational abscesses …
Sudden onset diffuse erythema and oedema of the breast
A 40 year old premenopausal white woman presented to a general gynaecologist with diffuse redness, swelling, and rapidly progressive pain in her left breast. She did not have a fever. Her medical history included one full term pregnancy with spontaneous delivery 19 years earlier. Her maternal grandmother had died of breast cancer at age 65 years. On physical examination, a warm and painful diffuse oedematous erythema was found in the inner quadrants of the breast (fig 1⇓), but she was otherwise in good general health. ### 1. On the basis of the history and examination findings, what are the differential diagnoses and the probable diagnosis? #### Short answer Non-lactational mastitis, cellulitis, abscess, and inflammatory breast cancer (IBC). Figure 1⇑ shows a classic presentation of IBC. #### Discussion Breast masses require triple test evaluation—physical examination, radiological examination, and needle biopsy—the results of which must all agree. IBC is diagnosed on clinical grounds, so the physical examination is key. The classic findings are diffuse erythema and oedema with bulging intradermal lymphatics enveloping more than a third of the breast, as well as the absence of systemic symptoms such as malaise and fever. The differential diagnosis in this setting, based on the physical examination, includes non-lactational mastitis, cellulitis, abscess, and inflammatory breast cancer. Non-lactational abscesses …
- 1 March 2015
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 186, 26-33
Limited efficacy of platinum-based adjuvant treatment on the outcome of borderline ovarian tumors
- 1 March 2015
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 186, 26-33
Limited efficacy of platinum-based adjuvant treatment on the outcome of borderline ovarian tumors
- Open Access
- 1 February 2015
- Published by Georg Thieme Verlag KG in Geburtshilfe und Frauenheilkunde
- Vol. 75 (02) , 183-187
Multifocal Tumorous Pseudoangiomatous Stromal Hyperplasia Presenting as Asymmetric Bilateral Breast Enlargement
PASH is a benign proliferation of stromal myofibroblasts that affects mostly premenopausal women and typically shows estrogen and progesterone receptor expression, allowing speculation regarding a hormonal cause. It usually presents as an incidental finding on a mammogram or as a palpable mass. We present a case of diffuse asymmetrical massive breast enlargement in a premenopausal woman with history of previous multiple PASH excisions for recurrent lesions, caused by multifocal tumorous PASH virtually replacing the breast parenchyma. Immunohistochemistry examination showed no hormone receptor expression. Despite its benign nature, such presentation of PASH is managed with bilateral mastectomy and immediate reconstruction with expanders for cosmetic and comfort reasons, while tumor excision or expectant management is deemed to lead to recurrence and progression. Although a hormonal origin is speculated based on hormone expression studies and typical patient profile, this case showed 0 % estrogen/progesterone expression in the final histology specimen. PASH ist eine gutartige Proliferation der stromalen Myofibroblasten. Betroffen sind überwiegend prämenopausale Frauen. Die typischerweise vorliegende Estrogen-/Progesteron-Rezeptorexpression legt die Vermutung einer hormonellen Ursache nahe. Häufig zeigt sich die PASH zufällig in der Mammografie oder als tastbarer Herd in der Mamma. Wir stellen den Fall einer massiven asymmetrischen Makromastie bei einer prämenopausalen Frau vor, die anamnestisch mehrere vorangegangene Tumorektomien wegen rezidivierenden PASH–Herden hatte. Nahezu das gesamte Brustdrüsenparenchym wurde durch die multifokalen tumorösen PASH-Herde ersetzt. Ungeachtet der Gutartigkeit der Herde wurde bei der Patientin eine bilaterale Mastektomie mit Sofortrekonstruktion mit Implantaten aus kosmetischen Gründen durchgeführt, da ein abwartendes Verhalten zu einer weiteren Progression geführt hätte. Trotz der Vermutung einer hormonellen Ursache der PASH zeigte unser Fall keine Hormonrezeptorexpression.
- 1 February 2015
- Published by Georg Thieme Verlag KG in Geburtshilfe und Frauenheilkunde
- Vol. 75 (02) , 183-187
Open AccessMultifocal Tumorous Pseudoangiomatous Stromal Hyperplasia Presenting as Asymmetric Bilateral Breast Enlargement
PASH is a benign proliferation of stromal myofibroblasts that affects mostly premenopausal women and typically shows estrogen and progesterone receptor expression, allowing speculation regarding a hormonal cause. It usually presents as an incidental finding on a mammogram or as a palpable mass. We present a case of diffuse asymmetrical massive breast enlargement in a premenopausal woman with history of previous multiple PASH excisions for recurrent lesions, caused by multifocal tumorous PASH virtually replacing the breast parenchyma. Immunohistochemistry examination showed no hormone receptor expression. Despite its benign nature, such presentation of PASH is managed with bilateral mastectomy and immediate reconstruction with expanders for cosmetic and comfort reasons, while tumor excision or expectant management is deemed to lead to recurrence and progression. Although a hormonal origin is speculated based on hormone expression studies and typical patient profile, this case showed 0 % estrogen/progesterone expression in the final histology specimen. PASH ist eine gutartige Proliferation der stromalen Myofibroblasten. Betroffen sind überwiegend prämenopausale Frauen. Die typischerweise vorliegende Estrogen-/Progesteron-Rezeptorexpression legt die Vermutung einer hormonellen Ursache nahe. Häufig zeigt sich die PASH zufällig in der Mammografie oder als tastbarer Herd in der Mamma. Wir stellen den Fall einer massiven asymmetrischen Makromastie bei einer prämenopausalen Frau vor, die anamnestisch mehrere vorangegangene Tumorektomien wegen rezidivierenden PASH–Herden hatte. Nahezu das gesamte Brustdrüsenparenchym wurde durch die multifokalen tumorösen PASH-Herde ersetzt. Ungeachtet der Gutartigkeit der Herde wurde bei der Patientin eine bilaterale Mastektomie mit Sofortrekonstruktion mit Implantaten aus kosmetischen Gründen durchgeführt, da ein abwartendes Verhalten zu einer weiteren Progression geführt hätte. Trotz der Vermutung einer hormonellen Ursache der PASH zeigte unser Fall keine Hormonrezeptorexpression.
- Open Access
- 19 January 2015
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 20 (2) , 151-158
A Meta-Analysis on the Impact of Platinum-Based Adjuvant Treatment on the Outcome of Borderline Ovarian Tumors With Invasive Implants
Background.: Treatment of borderline ovarian tumors (BOTs) remains contentious, and there is no consensus regarding therapy for BOTs with invasive implants (BOTi). The benefits of platinum-based adjuvant treatment were evaluated in patients with BOTi at primary diagnosis. Methods.: The PubMed database was systematically searched for articles using the following terms: ((borderline) OR (low malignant potential) AND (ovarian)) AND ((tumor) OR (cancer)) AND (invasive implants) AND ((follow-up) OR (survival) OR (treatment) OR (chemotherapy) OR (adjuvant treatment) OR (surgery) OR (surgical treatment)). Results.: We identified 27 articles including 3,124 patients, 181 with invasive implants. All studies provided information regarding mortality or recurrence rates. Central pathological examination was performed in 19 studies. Eight studies included more than 75% stage I patients; 7 included only advanced-stage patients, and 14 included only serous BOT. The pooled recurrence estimates for both treatment groups (adjuvant treatment: 44.0%, upfront surgery: 21.3%) did not differ significantly (p = .114). A meta-analysis of the 6 studies providing separate mortality data for both treatment groups favored surgical treatment only, but this difference did not reach statistical significance (.05 < p < .1; odds ratio: 0.33; 95% confidence interval: 0.09–1.71; p = .086). We were unable to pool the results of the included studies because not all studies registered events in both treatment groups. Egger's regression indicated low asymmetry of the studies (p = .39), and no heterogeneity was found (I2 = 0%). Conclusion.: We did not find evidence supporting platinum-based adjuvant therapy for BOT with invasive implants.
- 19 January 2015
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 20 (2) , 151-158
Open AccessA Meta-Analysis on the Impact of Platinum-Based Adjuvant Treatment on the Outcome of Borderline Ovarian Tumors With Invasive Implants
Background.: Treatment of borderline ovarian tumors (BOTs) remains contentious, and there is no consensus regarding therapy for BOTs with invasive implants (BOTi). The benefits of platinum-based adjuvant treatment were evaluated in patients with BOTi at primary diagnosis. Methods.: The PubMed database was systematically searched for articles using the following terms: ((borderline) OR (low malignant potential) AND (ovarian)) AND ((tumor) OR (cancer)) AND (invasive implants) AND ((follow-up) OR (survival) OR (treatment) OR (chemotherapy) OR (adjuvant treatment) OR (surgery) OR (surgical treatment)). Results.: We identified 27 articles including 3,124 patients, 181 with invasive implants. All studies provided information regarding mortality or recurrence rates. Central pathological examination was performed in 19 studies. Eight studies included more than 75% stage I patients; 7 included only advanced-stage patients, and 14 included only serous BOT. The pooled recurrence estimates for both treatment groups (adjuvant treatment: 44.0%, upfront surgery: 21.3%) did not differ significantly (p = .114). A meta-analysis of the 6 studies providing separate mortality data for both treatment groups favored surgical treatment only, but this difference did not reach statistical significance (.05 < p < .1; odds ratio: 0.33; 95% confidence interval: 0.09–1.71; p = .086). We were unable to pool the results of the included studies because not all studies registered events in both treatment groups. Egger's regression indicated low asymmetry of the studies (p = .39), and no heterogeneity was found (I2 = 0%). Conclusion.: We did not find evidence supporting platinum-based adjuvant therapy for BOT with invasive implants.
- 5 November 2013
- Published by Taylor & Francis in Epigenetics
- Vol. 8 (11) , 1226-1235
The cellular ratio of immune tolerance (immunoCRIT) is a definite marker for aggressiveness of solid tumors and may explain tumor dissemination patterns
The adaptive immune system is involved in tumor establishment and aggressiveness. Tumors of the ovaries, an immune-privileged organ, spread via transceolomic routes and rarely to distant organs. This is contrary to tumors of non-immune privileged organs, which often disseminate hematogenously to distant organs. Epigenetics-based immune cell quantification allows direct comparison of the immune status in benign and malignant tissues and in blood. Here, we introduce the “cellular ratio of immune tolerance” (immunoCRIT) as defined by the ratio of regulatory T cells to total T lymphocytes. The immunoCRIT was analyzed on 273 benign tissue samples of colorectal, bronchial, renal and ovarian origin as well as in 808 samples from primary colorectal, bronchial, mammary and ovarian cancers. ImmunoCRIT is strongly increased in all cancerous tissues and gradually augmented strictly dependent on tumor aggressiveness. In peripheral blood of ovarian cancer patients, immunoCRIT incrementally increases from primary diagnosis to disease recurrence, at which distant metastases frequently occur. We postulate that non-pathological immunoCRIT values observed in peripheral blood of immune privileged ovarian tumor patients are sufficient to prevent hematogenous spread at primary diagnosis. Contrarily, non-immune privileged tumors establish high immunoCRIT in an immunological environment equivalent to the bloodstream and thus spread hematogenously to distant organs. In summary, our data suggest that the immunoCRIT is a powerful marker for tumor aggressiveness and disease dissemination.
- 5 November 2013
- Published by Taylor & Francis in Epigenetics
- Vol. 8 (11) , 1226-1235
The cellular ratio of immune tolerance (immunoCRIT) is a definite marker for aggressiveness of solid tumors and may explain tumor dissemination patterns
The adaptive immune system is involved in tumor establishment and aggressiveness. Tumors of the ovaries, an immune-privileged organ, spread via transceolomic routes and rarely to distant organs. This is contrary to tumors of non-immune privileged organs, which often disseminate hematogenously to distant organs. Epigenetics-based immune cell quantification allows direct comparison of the immune status in benign and malignant tissues and in blood. Here, we introduce the “cellular ratio of immune tolerance” (immunoCRIT) as defined by the ratio of regulatory T cells to total T lymphocytes. The immunoCRIT was analyzed on 273 benign tissue samples of colorectal, bronchial, renal and ovarian origin as well as in 808 samples from primary colorectal, bronchial, mammary and ovarian cancers. ImmunoCRIT is strongly increased in all cancerous tissues and gradually augmented strictly dependent on tumor aggressiveness. In peripheral blood of ovarian cancer patients, immunoCRIT incrementally increases from primary diagnosis to disease recurrence, at which distant metastases frequently occur. We postulate that non-pathological immunoCRIT values observed in peripheral blood of immune privileged ovarian tumor patients are sufficient to prevent hematogenous spread at primary diagnosis. Contrarily, non-immune privileged tumors establish high immunoCRIT in an immunological environment equivalent to the bloodstream and thus spread hematogenously to distant organs. In summary, our data suggest that the immunoCRIT is a powerful marker for tumor aggressiveness and disease dissemination.